Oventus Medical's Annual General Meeting Highlights

  • Nov 22, 2019 AEDT
  • Team Kalkine

Oventus Medical Ltd (ASX: OVN) conducted its AGM today:

  • Significant progress was made in commercialising the new treatment platform for Obstructive Sleep Apnoea in the previous year.
  • OVN achieved major milestones- the launch of its ‘lab in lab’ clinical delivery model to streamline patients’ access to treatment by ensuring the sleep physician as well as dentist work together in the care of the patient, promoting choice, early intervention and support through their treatment.
  • Launched first five sites in October 2019 and OVN is in process of deploying a further 8 sites.
  • Additional contracts were signed with sleep groups in California and North Carolina.
  • Its latest product, the O2Vent® Optima was launched in Canada as well as Australia.


All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK